The Value of CYP2D6 and OPRM1 Pharmacogenetic Testing for Opioid Therapy

Clinics in Laboratory Medicine

Volumn 28, Issue 4, 2008, Pages 581-598

  Reynolds, Kristen K ^a,b   Ramey Hartung, Bronwyn ^a   Jortani, Saeed A ^a,b  

^a PGXL Laboratories   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; BIOLOGICAL MARKER; BUTORPHANOL; CODEINE; CYCLOOXYGENASE 2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DEXTROPROPOXYPHENE; HYDROCODONE; HYDROMORPHONE; IBUPROFEN; METHADONE; MORPHINE; MU 1 OPIATE RECEPTOR; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PETHIDINE; TRAMADOL; UNCLASSIFIED DRUG;

AGGRESSION; ARTHRITIS; ARTICLE; CANCER PAIN; CONVULSION; DRUG ABUSE; DRUG USE; ENVIRONMENTAL FACTOR; FEMALE INFERTILITY; FLUSHING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HEARING LOSS; HEREDITY; HUMAN; LIBIDO DISORDER; LOW BACK PAIN; MALE INFERTILITY; MENTAL DISEASE; NAUSEA; NEPHROTOXICITY; ORTHOSTATIC HYPOTENSION; PAIN; PHARMACODYNAMICS; PHARMACOGENETICS; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RESPIRATION DEPRESSION; RISK FACTOR; SIDE EFFECT; SOCIAL PSYCHOLOGY; SOMNOLENCE; STOMACH MOTILITY; VOMITING; WORLD HEALTH ORGANIZATION;

ANALGESICS, OPIOID; CYTOCHROME P-450 CYP2D6; DRUG TOLERANCE; GENETIC SCREENING; GENOTYPE; HUMANS; OPIOID-RELATED DISORDERS; PAIN; PAIN MEASUREMENT; RECEPTORS, OPIOID, MU;

EID: 57049087575     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2008.10.003     Document Type: Article

References (62)

1. Rasor J., and Harris G. Using opioids for patients with moderate to severe pain. J Am Osteopath Assoc 107 9 Suppl 5 (2007) ES4-ES10
2. Pain in the workplace-a 10-year update of Ortho-McNeil's survey on the impact of pain on the workplace (2006), PriCara, Unit of Ortho-McNeil Pharmaceutical Inc., Titusville (NJ)
3. Stewart W.F., Ricci J.A., Chee E., et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 290 (2003) 2443-2454
4. Ventafridda V., Saita L., Ripamonti C., et al. WHO guidelines for the use of analgesics in cancer pain. Int J Tissue React 7 (1985) 93-96
5. Sepulveda C., Marlin A., Yoshida T., et al. Palliative care: the World Health Organization's global perspective. J Pain Symptom Manage 24 (2002) 91-96
6. Jadad A.R., and Browman G.P. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 274 (1995) 1870-1873
7. Azevedo S.L., Ferreira K., Kimura M., et al. The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it?. Support Care Cancer 14 (2006) 1086-1093
8. Krenzischek D.A., Dunwoody C.J., Polomano R.C., et al. Pharmacotherapy for acute pain: implications for practice. J Perianesth Nurs 23 (2008) S28-S42
9. Gajraj N.M. COX-2 inhibitors celecoxib and parecoxib: valuable options for postoperative pain management. Curr Top Med Chem 7 (2007) 235-249
10. Martinez-Gonzalez J., and Badimon L. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr Pharm Des 13 (2007) 2215-2227
11. Gutstein H.B., and Akil H. Opioid analgesics. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics. 11th edition (2006), McGraw-Hill, New York 547-590
12. Dhawan B.N., Cesselin F., Raghubir R., et al. International union of pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 48 (1996) 567-592
13. Schlaepfer T.E., Strain E.C., Greenberg B.D., et al. Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects. Am J Psychiatry 155 (1998) 470-473
14. Cone E.J., Heit H.A., Caplan Y.H., et al. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J Anal Toxicol 30 (2006) 1-5
15. Beaver W.T., Wallenstein S.L., Rogers A., et al. Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone. J Pharmacol Exp Ther 207 (1978) 92-100
16. Clotz M.A., and Nahata M.C. Clinical uses of fentanyl, sufentanil, and alfentanil. Clin Pharm 10 (1991) 581-593
17. Willens J.S., and Myslinski N.R. Pharmacodynamics, pharmacokinetics, and clinical uses of fentanyl, sufentanil, and alfentanil. Heart Lung 22 (1993) 239-251
18. Gorman A.L., Elliott K.J., and Inturrisi C.E. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 223 (1997) 5-8
19. Atcheson R., Rowbotham D.J., and Lambert D.G. Fentanyl inhibits the release of [3H]noradrenaline from SH-SY5Y human neuroblastoma cells. Br J Anaesth 72 (1994) 98-103
20. Galvagno A.M., Correll D.J., and Narang S. Safe oral equianalgesic opioid dosing for patients with moderate to severe pain. Resid Staff Physician 53 4 (2007) 17-25
21. Turturro M.A., Paris P.M., Yealy D.M., et al. Hydrocodone versus codeine in acute musculoskeletal pain. Ann Emerg Med 20 (1991) 1100-1103
22. In: Baselt R.C. (Ed). Disposition of toxic drugs and chemicals in man. 7th edition (2004), Biomedical Publications, Foster City 546
23. Palangio M., Wideman G.L., Keffer M., et al. Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of postoperative obstetric or gynecologic pain. Clin Ther 22 (2000) 600-612
24. Palangio M., Damask M.J., Morris E., et al. Combination hydrocodone and ibuprofen versus combination codeine and acetaminophen for the treatment of chronic pain. Clin Ther 22 (2000) 879-892
25. Rodriguez R.F., Castillo J.M., Castillo M.P., et al. Hydrocodone/acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a double-blind comparative trial. Clin J Pain 24 (2008) 1-4
26. Friedman R.A., House J.W., Luxford W.M., et al. Profound hearing loss associated with hydrocodone/acetaminophen abuse. Am J Otol 21 (2000) 188-189
27. Ballantyne J.C. Opioid analgesia: perspectives on right use and utility. Pain Physician 10 (2007) 479-491
28. Fields H.L., and Martin J.B. Pain: pathophysiology and management. In: Fauci A.S., Braunwald E., and Kasper D.L. (Eds). Harrison's principles of internal medicine. 17th edition (2008), McGraw-Hill, New York 81-87
29. Vallerand A.H. The use of long-acting opioids in chronic pain management. Nurs Clin North Am 38 3 (2003) 435-445
30. SUPPORT study principal investigators. A controlled trial to improve care for seriously ill hospitalized patients. JAMA 274 20 (1995) 1591-1598
31. Gilson A.M., Joranson D.E., and Mauer M.A. Improving medical board policies: influence of a model. J Law Med Ethics 31 (2003) 128
32. Reynolds K.K., Valdes Jr. R., Hartung B.R., et al. Individualizing warfarin therapy. Pers Med 4 1 (2007) 11-31
33. Starch R. Chronic pain in America: roadblocks to relief. Amer Acad Pain Med, Amer Pain Soc, and Janssen Pharmaceutica 1999.
34. Gasche Y., Daali Y., Fathi M., et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351 27 (2004) 2827-2831
35. Lurcott G. The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives hydrocodone and oxycodone. Anesth Prog 45 (1999) 154-156
36. Linder M.W., Evans W.E., and McLeod H.L. Application of pharmacogenetic principles to clinical pharmacology. In: Burton M.E. (Ed). Applied pharmacokinetics & pharmacodynamics: principles of therapeutic drug monitoring (2005), Lippincott Williams & Wilkins, Baltimore (MD) 165-185
37. Foster A., Mobley E., and Wang X. Complicated pain management in a CYP2D6 poor metabolizer. Pain Pract 7 4 (2007) 352-356
38. Caraco Y., Sheller J., and Wood A.J.J. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 278 3 (1996) 1165-1174
39. Otton A.V., Schadel M., Cheung S.W., et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 54 5 (1993) 463-472
40. Kirchheiner J., Brøsen K., Dahl M.L., et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104 3 (2001) 173-192
41. Kirchheiner J., Nickchen K., Bauer M., et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9 5 (2004) 442-473
42. Kirchheiner J., Schmidt H., Tzvetkov M., et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics 7 (2007) 257-265
43. Koren G., Cairns J., Chitayat D., et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368 9536 (2006) 704
44. U.S. Food and Drug Administration. Use of codeine by some breastfeeding mothers may lead to life-threatening side effects in nursing babies. FDA Public Health Advisory (2007). http://www.fda.gov/CDER/Drug/advisory/codeine.htm Accessed October 10, 2008
45. Piestrzeniewicz M.K., Fichna J., and Janecka A. Opioid receptors and their selective ligands. Postepy Biochem 52 (2006) 313-319
46. Martin W.R., Eades C.G., Thompson J.A., et al. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197 (1976) 517-532
47. Steinfels G.F., Alberici G.P., Tam S.W., et al. Biochemical, behavioral, and electrophysiologic actions of the selective sigma receptor ligand (+)-pentazocine. Neuropsychopharmacology 1 (1998) 321-327
48. New D.C., and Wong Y.H. The ORL1 receptor: molecular pharmacology and signalling mechanisms. Neurosignals 11 (2002) 197-212
49. Yeon K.Y., Sim M.Y., Choi S.Y., et al. Molecular mechanisms underlying calcium current modulation by nociceptin. Neuroreport 15 (2004) 2205-2209
50. Ananthan S. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. AAPS J 8 (2006) E118-E125
51. Pasternak G.W. Insights into mu opioid pharmacology: the role of mu opioid receptor subtypes. Life Sci 68 (2001) 2213-2219
52. Kreek M.J., Bart G., Lilly C., et al. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 57 1 (2005) 1-26
53. Zhang Y., Wang D., Johnson A.D., et al. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biolumin Chemilumin 280 (2005) 32618-32624
54. Bond C., LaForge K.S., Tian M., et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95 16 (1998) 9608-9613
55. Beyer A., Koch T., Schroder H., et al. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89 (2004) 553-560
56. Fillingim R.B., Kaplan L., Staud R., et al. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 6 (2005) 159-167
57. Lotsch J., and Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics 6 3 (2006) 200-210
58. Reyes-Gibby C.C., Shete S., Rakvåg T., et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130 1-2 (2007) 25-30
59. Klepstad P., Rakvåg T.T., Kaasa S., et al. The 118A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48 10 (2004) 1232-1239
60. Lotsch J., Skarke C., Liefhold J., et al. Genetic predictors of the clinical response to opioid analgesics. Clin Pharm 43 14 (2004) 983-1013
61. de Leon J., Dinsmore L., and Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol 23 4 (2003) 420-421
62. Susce M.T., Murray-Carmichael E., and de Leon J. Response to hydrocodone, codeine, and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry 30 7 (2006) 1356-1358